political views Could 'AI' Become a Partner in Breast Cancer Care? getting to know

political views Could 'AI' Become a Partner in Breast Cancer Care? getting to know

over the years Could 'AI' Become a Partner in Breast Cancer Care? without borderlines
 
Photo :Could 'AI' Become a Partner in Breast Cancer Care?

shocked (*this news item will not be available after 01/15/2018) Tuesday, October 17, 2017 TUESDAY, Oct. 17, 2017 (HealthDay News) -- Machines armed with artificial intelligence may one day help doctors better identify high-risk breast lesions that might turn into cancer, new research suggests. High-risk breast lesions are abnormal cells found in a breast biopsy. These lesions pose a challenge to doctors and patients. The cells in such lesions aren't normal, but they're not cancerous either. And although they can develop into cancer, many don't. So, which ones need to be removed? "The decision about whether or not to proceed to surgery is challenging, and the tendency is to aggressively treat these lesions [and remove them]," said study author Dr. Manisha Bahl. "We felt like there must be a better way to risk-stratify these lesions," added Bahl, director of the breast imaging fellowship program at Massachusetts General Hospital. Working closely with computer scientists at Massachusetts Institute of Technology, researchers developed a "machine-learning" model to distinguish high-risk lesions that need to be surgically removed from those that could just be watched over time. Machine learning is a type of artificial intelligence. The computer model automatically learns and improves based on previous experiences, the researchers explained. The researchers gave the machine a lot of information about established risk factors, such as the type of lesion and patient age. The researchers also fed it the actual text from the biopsy report. Overall, there were 20,000 data elements included in the model, the researchers said. The test of the machine-learning model included information from slightly more than 1,000 women who had a high-risk lesion. About 96 percent of these women had their lesion surgically removed. Approximately 4 percent of women didn't have their lesions removed, but instead had two years of follow-up imaging tests. The model was trained with two-thirds of the cases, and tested on the remaining third. The test included 335 lesions. The machine correctly identified 37 of the 38 lesions (97 percent) that had developed into cancer, the study said. The model also would have helped women avoid one-third of surgeries on lesions that would have remained benign during the follow-up period. In addition, Bahl said, "the model picked up on text in the biopsy report -- the words severely and severely atypical conferred a higher risk of upgrade to cancer." Bahl said the researchers are hoping to incorporate mammography images and pathology slides into the machine learning model, with the goal of eventually including this in clinical practice. "Machine learning is a tool that we can use to improve patient care -- whether that means reducing unnecessary surgeries or being able to provide more information to patients so they can make more informed decisions," Bahl said. Dr. Bonnie Litvack is medical director of the women's imaging center at Northern Westchester Hospital in Mt. Kisco, N.Y. "Women should know that there is a new type of machine learning that's helped us identify high-risk lesions at low risk of cancer. And, we may soon have more information for them when they're faced with the decision of whether to have surgery to excise these high-risk lesions or not," said Litvak, who wasn't involved in the study. "Artificial intelligence is an exciting field that will help us give women more data and help with shared decision-making," Litvack added. The study was published Oct. 17 in Radiology . SOURCES: Manisha Bahl, M.D., M.P.H., director, breast imaging fellowship program, Massachusetts General Hospital, and assistant professor, radiology, Harvard Medical School, Boston; Bonnie Litvack, M.D., medical director, women's imaging center, Northern Westchester Hospital, Mt. Kisco, N.Y.; Oct. 17, 2017, Radiology HealthDay Copyright (c) 2017 HealthDay . All rights reserved. News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services. More Health News on Breast Cancer Recent Health News the reality


constantly Could 'AI' Become a Partner in Breast Cancer Care? take into account that
at midnight Be Wary of Shopping for Pet Meds Online discover

at midnight Be Wary of Shopping for Pet Meds Online discover

and mock Be Wary of Shopping for Pet Meds Online tense
 
Photo :Be Wary of Shopping for Pet Meds Online

picks (*this news item will not be available after 01/15/2018) By Robert Preidt Tuesday, October 17, 2017 TUESDAY, Oct. 17, 2017 (HealthDay News) -- If you get medications online for your pets, be careful, the U.S. Food and Drug Administration cautions. Some websites sell unapproved or counterfeit drugs, make fraudulent claims, sell prescription drugs without requiring a prescription, or sell expired drugs. As a result, you could buy drugs that are unsafe or ineffective for your pet. When ordering pet medications online be sure you're dealing with a reputable pharmacy. One way to do that is to look for pharmacy websites ending in ".Pharmacy," said Dr. Martine Hartogensis, deputy director of the Office of Surveillance and Compliance in the FDA's Center for Veterinary Medicine. Or order your pet medications from an outsourced prescription management service that's used by your veterinarian. These state-licensed internet pharmacy services work directly with the veterinarian. These pharmacies also require a prescription be written by the veterinarian. Check if your veterinarian uses an internet pharmacy service. It's also important to first consult your veterinarian. An online pharmacy may claim that one of its veterinarians will assess your pet based on written information you provide, with no need for a physical examination. But that could be a warning sign that the pharmacy is not legitimate. Going online to buy two types of widely used veterinary drugs -- heartworm preventives and nonsteroidal anti-inflammatory drugs -- can be especially risky. "Both types of drugs can be dangerous if your vet doesn't get involved," Hartogensis said in an FDA news release. "It's not generally a concern if you use a legitimate online pharmacy and mail in a prescription from your veterinarian, who is monitoring your pet. But if there is no veterinarian-client-patient relationship, it's a dangerous practice," she warned. SOURCE: U.S. Food and Drug Administration, news release, Oct. 11, 2017 HealthDay Copyright (c) 2017 HealthDay . All rights reserved. News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services. More Health News on Pet Health Recent Health News on occasion


an inherent ability Be Wary of Shopping for Pet Meds Online of what is
flats Sleep Aid at the moment

flats Sleep Aid at the moment

modern Sleep Aid a quirky
 
Photo :Sleep Aid

without warning Sleep Aid Generic Name: Doxylamine (dox IL a meen) Brand Name: Doxytex, Nitetime Sleep-Aid, Sleep Aid Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings User Reviews Support Group Q & A Uses of Sleep Aid: It is used to treat sleep problems. What do I need to tell my doctor BEFORE I take Sleep Aid? For all patients taking Sleep Aid (doxylamine): If you have an allergy to doxylamine or any other part of this medicine. If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs. Children: If your child is younger than 12 years of age. Do not give Sleep Aid to a child younger than 12 years of age. This medicine may interact with other drugs or health problems. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this medicine with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. Slideshow Insomnia Treatment: Non-Benzodiazepines Ambien, Lunesta & Sonata What are some things I need to know or do while I take Sleep Aid? Tell all of your health care providers that you take Sleep Aid. This includes your doctors, nurses, pharmacists, and dentists. Avoid driving and doing other tasks or actions that call for you to be alert after you take this medicine. You may still feel sleepy the day after you take Sleep Aid. Avoid these tasks or actions until you feel fully awake. Avoid drinking alcohol while taking this medicine. Talk with your doctor before you use other drugs and natural products that slow your actions. Be careful in hot weather or while being active. Drink lots of fluids to stop fluid loss. If you are 65 or older, use Sleep Aid with care. You could have more side effects. Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this medicine while you are pregnant. Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby. How is this medicine (Sleep Aid) best taken? Use Sleep Aid as ordered by your doctor. Read all information given to you. Follow all instructions closely. Take 30 minutes before bedtime. Do not take this medicine for more than 2 weeks unless told to do so by your doctor. What do I do if I miss a dose? If you take Sleep Aid on a regular basis, take a missed dose as soon as you think about it. If you will not be able to get a full night's sleep (at least 7 hours) after taking the missed dose, skip the missed dose and go back to your normal time. Do not take 2 doses at the same time or extra doses. Many times this medicine is taken on an as needed basis. Do not take more often than told by the doctor. Dosage Information (comprehensive) What are some side effects that I need to call my doctor about right away? WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat. Not sweating during activities or in warm temperatures. Not able to pass urine. Trouble passing urine. Feeling very tired or weak. Change in eyesight. A fast heartbeat. A heartbeat that does not feel normal. What are some other side effects of Sleep Aid? All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away: Feeling sleepy. Dizziness. Hard stools (constipation). Dry mouth. Thickening of mucus in nose or throat. These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch. Side Effects (complete list) If OVERDOSE is suspected: If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened. How do I store and/or throw out Sleep Aid? Store in the original container at room temperature. Store in a dry place. Do not store in a bathroom. Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets. Check with your pharmacist about how to throw out unused drugs. Consumer Information Use and Disclaimer If your symptoms or health problems do not get better or if they become worse, call your doctor. Do not share your drugs with others and do not take anyone else's drugs. Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor. Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins. Some drugs may have another patient information leaflet. Check with your pharmacist. If you have any questions about Sleep Aid (doxylamine), please talk with your doctor, nurse, pharmacist, or other health care provider. If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened. This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about Sleep Aid. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using Sleep Aid. Review Date: November 1, 2017 Next Side Effects Print this page Add to My Med List More about Sleep Aid (doxylamine) Side Effects During Pregnancy Dosage Information Drug Interactions Support Group 4 Reviews Add your own review/rating Drug class: miscellaneous anxiolytics, sedatives and hypnotics Consumer resources Other brands: Unisom SleepTabs , Doxytex , Nighttime Sleepaid Professional resources Good Neighbor Sleep Aid (FDA) ... +8 more Related treatment guides Insomnia Drug Status Rx OTC Availability Rx and/or OTC B Pregnancy Category No proven risk in humans N/A CSA Schedule Not a controlled drug Sleep Aid Rating 4 User Reviews 8.0 /10 4 User Reviews 8.0 Rate it! Drug Class Miscellaneous anxiolytics, sedatives and hypnotics Related Drugs Insomnia melatonin , lorazepam , zolpidem , amitriptyline , Ambien , temazepam , Ativan , diphenhydramine , doxepin , Elavil , Restoril , Ibuprofen PM , Belsomra , Lunesta , eszopiclone , Rozerem , triazolam , zaleplon , doxylamine , Sonata , Silenor , Halcion , flurazepam , ramelteon , More... Related: Insomnia advantage of


one and all Sleep Aid exercise session
doing some Skip Opioid Treatment for Migraine in the ER aggravating

doing some Skip Opioid Treatment for Migraine in the ER aggravating

fee Skip Opioid Treatment for Migraine in the ER enterprise
 
Photo :Skip Opioid Treatment for Migraine in the ER

looking forward to (*this news item will not be available after 01/16/2018) By Mary Elizabeth Dallas Wednesday, October 18, 2017 WEDNESDAY, Oct. 18, 2017 (HealthDay News) -- For people seeking treatment for a migraine in the emergency room, a commonly prescribed opioid called hydromorphone (Dilaudid or Exalgo) doesn't seem to work as well as at least one other medication, a new study finds. "People go to U.S. emergency departments 1.2 million times a year with migraine, and the opioid drug hydromorphone is used in 25 percent of these visits, yet there have been no randomized, high-quality studies on its use for acute migraine," said study author Dr. Benjamin Friedman. He is with the department of emergency medicine at the Albert Einstein College of Medicine in New York City. Doctors should consider available alternatives before giving patients the opioid painkiller, the study authors suggested in a news release from the American Academy of Neurology. For the study, researchers investigated if opioid use led to addiction among 127 patients who made repeated trips to two emergency departments in New York for treatment of migraines. Half of the people were treated with hydromorphone. The remaining patients were given prochlorperazine through an IV. This drug works by blocking the release of a brain chemical called dopamine. The researchers looked at how many of the patients had migraine relief for at least 48 hours. The study was halted after the 127 patients were enrolled because the results showed that prochlorperazine worked dramatically better than hydromorphone. After 48 hours, 60 percent of the patients on prochlorperazine had prolonged headache relief, compared with 31 percent of the people treated with hydromorphone. In the emergency room, 31 percent of those who received hydromorphone asked for a second dose of the drug. The same was true for only 8 percent of those who received prochlorperazine. Of the patients on hydromorphone, 36 percent asked for other painkillers, compared with only 6 percent of the prochlorperazine group, according to the report. There was no difference in how often the patients from both treatment groups returned to the ER due to a migraine within one month of the treatment, the researchers pointed out. Friedman noted that patients who had used opioids within the past 30 days or had a history of addiction to these drugs were excluded from the study. Therefore, the study participants may have been at lower risk for an opioid abuse problem than people in the general population. "While this study demonstrates the overwhelming superiority of prochlorperazine over hydromorphone for initial treatment of acute migraine, the results do not suggest that treatment with IV opioids leads to long-term addiction," Friedman said. "In addition, the results should not be used to avoid the use of opioids for people who have not responded well to anti-dopaminergic drugs [such as prochlorperazine]," he added. The study was published online Oct. 18 in the journal Neurology . SOURCE: American Academy of Neurology, news release, Oct. 18, 2017 HealthDay Copyright (c) 2017 HealthDay . All rights reserved. News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services. More Health News on Emergency Medical Services Medicines Migraine Recent Health News is in general


adjustments Skip Opioid Treatment for Migraine in the ER irritating
it is important Skyla remains

it is important Skyla remains

could Skyla sporting activities
 
Photo :Skyla

prescribed drugs Skyla Generic Name: Levonorgestrel (IUD) (LEE voe nor jes trel) Brand Name: Kyleena, Liletta (52 MG), Mirena (52 MG), Skyla Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings User Reviews Support Group Q & A Compare Alternatives Pricing & Coupons Uses of Skyla: It is used to prevent pregnancy. It is used to treat heavy bleeding during monthly periods (menstruation). Slideshow Birth Control: Your Contraceptive Questions Answered What do I need to tell my doctor BEFORE I take Skyla? If you have an allergy to Skyla (levonorgestrel (IUD)) or any part of this medicine. If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs. If you are pregnant or may be pregnant. Do not use Skyla if you are pregnant. If you have an IUD (intrauterine device) in place. If you have any of these health problems: Active liver disease, chlamydia or gonorrhea, endometritis after a birth, genital tract infection, infected abortion in the last 3 months, liver tumor, pelvic infection, uterine or cervical tumor or growth, uterine problems like uterine fibroids, or untreated cervicitis or vaginitis. If you have unexplained vaginal bleeding. If you have ever had any of these health problems: Breast cancer, cancer where hormones make it grow, or pelvic inflammatory disease. If you have not started your period. If you or your partner have sex with more than one person. If your body is weak at fighting infections. If you have ever abused drugs. This is not a list of all drugs or health problems that interact with this medicine. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take Skyla with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take Skyla? Tell all of your health care providers that you take this medicine. This includes your doctors, nurses, pharmacists, and dentists. Follow up with the doctor as you have been told. Based on when Skyla is put in, you may need to use a non-hormone type of birth control like condoms to prevent pregnancy for some time. Follow what your doctor has told you to do about when to have this medicine put in and using a non-hormone type of birth control. This medicine is not for use as emergency birth control. Talk with the doctor. This medicine does not stop the spread of diseases like HIV or hepatitis that are passed through blood or having sex. Do not have any kind of sex without using a latex or polyurethane condom. Do not share needles or other things like toothbrushes or razors. Talk with your doctor. If you are having an MRI, talk with your doctor. Life-threatening infection can happen within a few days after Skyla was put in. Call your doctor right away if you have fever or pain where this medicine was placed. Very bad health problems and the need for surgery can happen if Skyla goes through the uterus. This medicine may also not prevent pregnancy if this happens. Talk with the doctor. This medicine may raise the chance of a health problem called pelvic inflammatory disease (PID). The chance may be higher if you or your partner have sex with other partners. PID can lead to other health problems like not being able to get pregnant, surgery, or rarely death. Talk with your doctor. Vaginal bleeding, spotting, or cramps may happen for 3 to 6 months after this medicine has been put in. If these signs do not go away or are very bad, call your doctor right away. If you think Skyla has come out, call your doctor. You may get pregnant if this medicine comes out. Use another kind of birth control like a condom until you see your doctor. This medicine is not approved for use in women who are going through or have been through the change of life (menopause). Talk with your doctor. Periods may stop in some women after 1 year of using Skyla (levonorgestrel (IUD)). Periods will go back to normal when this medicine is taken out. If you do not have a period for 6 weeks when Skyla is in place, call your doctor. If you think you may be pregnant while this medicine is in place, call your doctor right away. Very bad and sometimes deadly health problems can happen when Skyla is removed or if it is left in place during pregnancy. This includes loss of fertility, infections, and loss of the unborn baby. Talk with your doctor about the risks of getting pregnant while this medicine is in place. Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby. How is this medicine (Skyla) best taken? Use Skyla as ordered by your doctor. Read all information given to you. Follow all instructions closely. This medicine will be given to you by a doctor. Some pain, bleeding, or other reactions may happen when this medicine is put in. These other reactions may include seizures, slow heartbeat, very bad dizziness, or passing out. Talk with your doctor. Check to see if Skyla is in place as you have been told by your doctor or read the package insert. If this medicine is being removed and you do not want to get pregnant, talk with your doctor. You will need to use another kind of birth control like a condom the week before it is removed. What do I do if I miss a dose? Call your doctor to find out what to do. Dosage Information (comprehensive) What are some side effects that I need to call my doctor about right away? WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat. Weakness on 1 side of the body, trouble speaking or thinking, change in balance, drooping on one side of the face, or blurred eyesight. Chest pain or pressure. Dizziness. Belly pain. Pelvic pain. Vaginal bleeding that is not normal. Vaginal itching or discharge. Fever or chills. A lump in the breast or breast soreness. Cannot feel string. Device comes out. Painful sex. Very bad headache. Any unexplained bruising or bleeding. Yellow skin or eyes. Mood changes. Low mood (depression). Genital sores. What are some other side effects of Skyla? All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away: Pimples (acne). Headache. Upset stomach or throwing up. These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch. Side Effects (complete list) If OVERDOSE is suspected: If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened. How do I store and/or throw out Skyla? If you need to store Skyla at home, talk with your doctor, nurse, or pharmacist about how to store it. Consumer Information Use and Disclaimer If your symptoms or health problems do not get better or if they become worse, call your doctor. Do not share your drugs with others and do not take anyone else's drugs. Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor. Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins. Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets. Check with your pharmacist about how to throw out unused drugs. Some drugs may have another patient information leaflet. Check with your pharmacist. If you have any questions about this medicine, please talk with your doctor, nurse, pharmacist, or other health care provider. If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened. This information should not be used to decide whether or not to take Skyla or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to Skyla (levonorgestrel (IUD)). This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine. Review Date: November 1, 2017 Next Side Effects Print this page Add to My Med List More about Skyla (levonorgestrel) Side Effects During Pregnancy Dosage Information Drug Interactions Compare Alternatives Support Group Pricing & Coupons En Espaรฑol 1147 Reviews Add your own review/rating Drug class: contraceptives Consumer resources Skyla Skyla (Advanced Reading) Other brands: Mirena , Plan B , Kyleena , Plan B One-Step , ... +10 more Professional resources Skyla IUD (FDA) Related treatment guides Birth Control} Drug Status Rx Availability Prescription only X Pregnancy Category Not for use in pregnancy N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Skyla Rating 1147 User Reviews 7.2 /10 1147 User Reviews 7.2 Rate it! Drug Class Contraceptives Progestins Related Drugs Birth Control medroxyprogesterone , Provera , Depo-Provera , norethindrone , Mirena , Nexplanon , Sprintec , levonorgestrel , NuvaRing , Ortho Tri-Cyclen , Yasmin , Yaz , TriNessa , Aviane , Lo Loestrin Fe , Apri , Alesse , Mononessa , Microgestin Fe 1 / 20 , Camila , Xulane , Seasonique , Lutera , Ortho Evra , Levora , More...} } many differing types


apologize Skyla you purchased
time off Newer Blood Thinners May Not Bring Higher Bleeding Risk the masses

time off Newer Blood Thinners May Not Bring Higher Bleeding Risk the masses

nail cropping Newer Blood Thinners May Not Bring Higher Bleeding Risk
 
Photo :Newer Blood Thinners May Not Bring Higher Bleeding Risk

generally (*this news item will not be available after 01/16/2018) Wednesday, October 18, 2017 WEDNESDAY, Oct. 18, 2017 (HealthDay News) -- New anti-clotting drugs -- like Xarelto, Pradaxa and Eliquis -- aren't linked with a higher risk of bleeding than the older drug warfarin, a new study finds. Many patients who suffer from blood clots in their legs -- called venous thromboembolism (VTE) -- or have the abnormal heart rhythm called atrial fibrillation take blood thinners to help prevent life-threatening clots that can travel to the heart, lung or brain. "Given the advantages associated with these new drugs not requiring frequent monitoring, our results suggest that they may be considered as a treatment option for patients with VTE who are candidates for receiving oral anticoagulant therapy," said lead researcher Min Jun. He is a senior research fellow at the University of New South Wales in Sydney, Australia. Jun cautioned, however, that the Canadian-Australian study was an observational one, so the possibility that results were due to other unmeasured factors cannot be excluded. The standard anti-clotting drug is warfarin. Although the drug is effective, it has to be closely monitored with frequent blood tests to ensure it provides protection without the risk of major bleeding. Newer anticoagulants, called direct oral anticoagulants, are as effective as warfarin and don't require constant blood tests. But whether they increase the risk for major bleeding has not been clear from clinical practice. That's important because only Pradaxa has an antidote that can stop bleeding should it occur. According to Dr. Byron Lee, "The direct oral anticoagulants have been getting a lot of bad press." Lee is director of electrophysiology laboratories and clinics at the University of California, San Francisco. "Late-night TV commercials about class-action lawsuits scare patients into believing these new drugs are dangerous," he said. The reality, Lee added, is that studies have shown that these new drugs are just as safe as warfarin, if not better. "Some of these drugs do not yet have a reversal agent, yet this study showed that in a real-world setting, these drugs are not leading to more major bleeds or deaths," Lee said. The one downside to these drugs is that they are often more expensive than warfarin, with higher co-pays, depending on the insurance plan. To see how these drugs performed, Jun and his colleagues identified nearly 60,000 patients in the United States and Canada who had been diagnosed with VTE and were prescribed warfarin or one of the newer drugs between January 2009 and March 2016. Over an average of 85 days of follow-up, slightly more than 3 percent of the patients had an episode of major bleeding and nearly 2 percent died. The risk of major bleeding was similar for both the newer anticoagulants and warfarin, the researchers found. And there was no difference in the risk of death, Jun said. These findings didn't change when patients were followed for up to six months, he added. However, Jun noted, "Further studies are needed to better understand the longer-term safety of these drugs among VTE patients as well as their safety among advanced chronic kidney disease patients, in whom the risk of major bleeding is greater compared with other patient groups." The report was published online Oct. 17 in BMJ . SOURCES: Min Jun, Ph.D., senior research fellow, University of New South Wales, Sydney, Australia; Byron Lee, M.D., professor, medicine, and director, electrophysiology laboratories and clinics, University of California, San Francisco; Oct. 17, 2017, BMJ , online HealthDay Copyright (c) 2017 HealthDay . All rights reserved. News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services. More Health News on Atrial Fibrillation Blood Thinners Deep Vein Thrombosis Recent Health News a number of


might Newer Blood Thinners May Not Bring Higher Bleeding Risk most recent
is in general Skyla every person

is in general Skyla every person

most pretty Skyla considered necessary
 
Photo :Skyla

advised Skyla Generic Name: levonorgestrel intrauterine system (LEE voe nor JES trel IN tra UE ter ine SIS tem) Brand Name: Kyleena, Liletta, Mirena, Skyla Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings User Reviews Support Group Q & A Compare Alternatives Pricing & Coupons What is levonorgestrel intrauterine system? Levonorgestrel is a female hormone that can cause changes in your cervix, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus. Levonorgestrel intrauterine system is a plastic device that is placed in the uterus where it slowly releases the hormone to prevent pregnancy for 3 to 5 years. Levonorgestrel intrauterine system is used to prevent pregnancy for up to 5 years. You may use this device whether you have children or not. Mirena is also used to treat heavy menstrual bleeding in women who choose to use an intrauterine form of birth control. Levonorgestrel is a progestin hormone and does not contain estrogen. The intrauterine device (IUD) releases levonorgestrel in the uterus, but only small amounts of the hormone reach the bloodstream. Levonorgestrel intrauterine system should not be used as emergency birth control. Levonorgestrel intrauterine system may also be used for purposes not listed in this medication guide. Slideshow Emergency Contraception Laid Bare - The 10 Biggest Myths Revealed What is the most important information I should know about levonorgestrel intrauterine system? You should not use this intrauterine device if you have abnormal vaginal bleeding, a pelvic infection, certain other problems with your uterus or cervix, or if you have breast or uterine cancer, liver disease or liver tumor, or a weak immune system. Do not use during pregnancy. Call your doctor if you miss a period or think you might be pregnant. What should I discuss with my healthcare provider before taking levonorgestrel intrauterine system? An intrauterine device can increase your risk of developing a serious pelvic infection, which may threaten your life or your future ability to have children. Ask your doctor about your personal risk. Do not use this IUD during pregnancy. This device can cause severe infection, miscarriage, premature birth, or death of the mother if left in place during pregnancy. Tell your doctor right away if you become pregnant. If you choose to continue a pregnancy that occurs while using a levonorgestrel intrauterine system, watch for signs of infection such as fever, chills, flu symptoms, cramps, vaginal bleeding or discharge. You should not use this device if you are allergic to levonorgestrel, silicone, silica, silver, barium, iron oxide, or polyethylene, or if you have: abnormal vaginal bleeding that has not been checked by a doctor; an untreated or uncontrolled pelvic infection (vaginal, cervical uterine, or bladder); endometriosis or a serious pelvic infection following a pregnancy or abortion within the past 3 months; a history of pelvic inflammatory disease (PID), unless you have had a normal pregnancy after the infection was treated and cleared; uterine fibroid tumors or other conditions that affect the shape of the uterus; past or present breast cancer, known or suspected cervical or uterine cancer; liver disease or liver tumor (benign or malignant); a recent abnormal Pap smear that has not yet been diagnosed or treated; a disease or condition that weakens your immune system, such as AIDS, leukemia, or IV drug abuse; or if you have another intrauterine device (IUD) in place. To make sure levonorgestrel is safe for you, tell your doctor if you have ever had: high blood pressure, heart disease or a heart valve disorder; a heart attack or stroke; a bleeding or blood-clotting disorder; migraine headaches; or a vaginal infection, pelvic infection, or sexually transmitted disease. You should not use this IUD if you are breast-feeding a baby younger than 6 weeks old. This IUD may be more likely to form a hole or get embedded in the wall of your uterus if you have the device inserted while you are breast-feeding. How is levonorgestrel intrauterine system used? Levonorgestrel intrauterine system is a T-shaped plastic device that is inserted through the vagina and placed into the uterus by a doctor. The device is usually inserted within 7 days after the start of a menstrual period. You may feel pain or dizziness during insertion of the IUD. You may also have minor vaginal bleeding. Tell your doctor if you still have these symptoms longer than 30 minutes. The levonorgestrel device should not interfere with sexual intercourse, wearing tampons, or using other vaginal medications. After each menstrual period, make sure you can still feel the removal strings. Wash your hands with soap and water, and insert your clean fingers into the vagina. You should be able to feel the strings at the opening of your cervix. Call your doctor at once if you cannot feel the strings, or if you think the device has slipped lower in your uterus or out of your uterus. A sudden increase in menstrual flow may be a sign that the device has slipped out of place. If you think the device is not properly in place, use a non-hormone method of birth control (condom, or diaphragm with spermicide) to prevent pregnancy until your doctor is able to replace the IUD. Your doctor will need to see you within a few weeks after insertion of the device to make sure it is still in place correctly. You will also need regular annual pelvic exams and Pap smears. You may have irregular periods during the first 3 to 6 months of use. Your flow may be lighter or heavier, and you may eventually stop having periods after several months. Call your doctor if you miss a period or think you might be pregnant. If you need to have an MRI (magnetic resonance imaging), tell your caregivers ahead of time that you have an IUD in place. Your device may be removed at any time you decide to stop using birth control. The Mirena or Kyleena intrauterine system must be removed at the end of the 5-year wearing time. The Skyla or Liletta device must be removed after 3 years. Your doctor can insert a new device at that time if you wish to continue using this form of birth control. Only your doctor should remove the IUD. Do not attempt to remove the device yourself. If you wish to continue preventing pregnancy, you may need to start using another birth control method a week before your levonorgestrel intrauterine system is removed. What happens if I miss a dose? Since the IUD continuously releases a low dose of levonorgestrel, missing a dose does not occur when using this form of levonorgestrel. What happens if I overdose? An overdose of levonorgestrel released from the intrauterine system is very unlikely to occur. What should I avoid while using levonorgestrel intrauterine system? Avoid having more than one sexual partner. The IUD can increase your risk of developing a serious pelvic infection, which is often caused by sexually transmitted disease. Levonorgestrel intrauterine system will not protect you from sexually transmitted diseases, including HIV and AIDS. Using a condom is the only way to help protect yourself from these diseases. Call your doctor if your sexual partner develops HIV or a sexually transmitted disease, or if you have any change in sexual relationships. Levonorgestrel intrauterine system side effects Get emergency medical help if you have severe pain in your lower stomach or side. This could be a sign of a tubal pregnancy (a pregnancy that implants in the fallopian tube instead of the uterus). A tubal pregnancy is a medical emergency. The levonorgestrel IUD may become embedded into the wall of the uterus, or may perforate (form a hole) in the uterus. If this occurs, the device may no longer prevent pregnancy, or it may move outside the uterus and cause scarring, infection, or damage to other organs. Your doctor may need to surgically remove the device. Call your doctor at once if you have: severe cramps or pelvic pain, pain during sexual intercourse; extreme dizziness or light-headed feeling; severe migraine headache; heavy or ongoing vaginal bleeding, vaginal sores, vaginal discharge that is watery, foul-smelling discharge, or otherwise unusual; pale skin, weakness, easy bruising or bleeding, fever, chills, or other signs of infection; sudden numbness or weakness (especially on one side of the body), confusion, problems with vision, sensitivity to light; jaundice (yellowing of the skin or eyes); or signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Common side effects may include: pelvic pain, vaginal itching or infection, irregular menstrual periods, changes in bleeding patterns or flow; stomach pain, nausea, vomiting, bloating; headache, depression, mood changes; back pain, breast tenderness or pain; weight gain, acne, changes in hair growth, loss of interest in sex; or puffiness in your face, hands, ankles, or feet. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Side Effects (complete list) What other drugs will affect levonorgestrel intrauterine system? Other drugs may interact with levonorgestrel, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using. Next Side Effects Print this page Add to My Med List More about Skyla (levonorgestrel) Side Effects During Pregnancy Dosage Information Drug Interactions Compare Alternatives Support Group Pricing & Coupons En Espaรฑol 1147 Reviews Add your own review/rating Drug class: contraceptives Consumer resources Skyla Skyla (Advanced Reading) Other brands: Mirena , Plan B , Kyleena , Plan B One-Step , ... +10 more Professional resources Skyla IUD (FDA) Related treatment guides Birth Control Where can I get more information? Your doctor or pharmacist can provide more information about the levonorgestrel intrauterine system. Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed. Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist. Copyright 1996-2012 Cerner Multum, Inc. Version: 7.02. Date modified: December 03, 2017 Last reviewed: July 28, 2017} Drug Status Rx Availability Prescription only X Pregnancy Category Not for use in pregnancy N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class Contraceptives Progestins Related Drugs Birth Control medroxyprogesterone , Provera , Depo-Provera , norethindrone , Mirena , Nexplanon , Sprintec , levonorgestrel , NuvaRing , Ortho Tri-Cyclen , Yasmin , Yaz , TriNessa , Aviane , Lo Loestrin Fe , Apri , Alesse , Mononessa , Microgestin Fe 1 / 20 , Camila , Xulane , Seasonique , Lutera , Ortho Evra , Levora , More... Skyla Rating 1147 User Reviews 7.2 /10 1147 User Reviews 7.2 Rate it! Related Questions & Answers How does Kyleena compare to Liletta, Mirena and Skyla? Skyla - Who is the distributor of this product? Birth Control - I got my skyla iud? Iud's and periods? Birth Control - How long do I have to wait to have an IUD inserted after stopping seasonique? Read more questions} } wonderful


well-deserved Skyla really appropriate
benefiting from Higher Doses of Vitamin D May Boost Preemies' Bone Health to influence

benefiting from Higher Doses of Vitamin D May Boost Preemies' Bone Health to influence

extraordinary Higher Doses of Vitamin D May Boost Preemies' Bone Health feel free
 
Photo :Higher Doses of Vitamin D May Boost Preemies' Bone Health

a protracted (*this news item will not be available after 01/16/2018) By Mary Elizabeth Dallas Wednesday, October 18, 2017 WEDNESDAY, Oct. 18, 2017 (HealthDay News) -- Higher doses of vitamin D can improve the bone health of premature babies, new research suggests. "We are hopeful that neonatologists will consider giving preterm infants 800 IUs [International Units]," said study author Dr. Ann Anderson Berry. She is medical director of the NICU Nebraska Medicine, the clinical partner of the University of Nebraska Medical Center. "We know that even with standard vitamin D dosing, we were still seeing a fair number of preterm infants who suffered from impaired bone health. This is another form of NICU [neonatal intensive care] therapy that can help decrease that risk," she said in a Nebraska news release. Premature and preterm infants are already routinely given vitamin D to help prevent weak bones and other conditions related to vitamin D deficiency, such as rickets. Dosages vary, however, and many infants still develop bone-related health issues. To see if there is an optimal dose for protecting bone health, scientists at the University of Nebraska Medical Center looked at changes in vitamin D in the blood of 32 premature babies over the course of four weeks. The babies, who were born at between 24 and 32 weeks of pregnancy, were given either 400 or 800 IU/day of vitamin D. After four weeks, the babies' bone density improved and they had greater levels of vitamin D in their blood. Their growth also improved, the study found. The study authors said they also found that doubling the typical dose of Vitamin D from 400 to 800 IUs could reduce the number of premature infants with extremely low bone density. The findings were published recently in the journal PLOS ONE . SOURCE: University of Nebraska Medical Center, news release, Oct. 11, 2017 HealthDay Copyright (c) 2017 HealthDay . All rights reserved. News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services. More Health News on Premature Babies Vitamin D Recent Health News official


doze off Higher Doses of Vitamin D May Boost Preemies' Bone Health weak spot
with reference to Firefighters Exposed to Carcinogens Through the Skin overlooked

with reference to Firefighters Exposed to Carcinogens Through the Skin overlooked

seems to be Firefighters Exposed to Carcinogens Through the Skin is widely known
 
Photo :Firefighters Exposed to Carcinogens Through the Skin

petering out (*this news item will not be available after 01/16/2018) By Robert Preidt Wednesday, October 18, 2017 WEDNESDAY, Oct. 18, 2017 (HealthDay News) -- Firefighters face many known hazards on the job, but one area that hasn't been well researched is how their skin's exposure to hazardous chemicals might increase their risk of cancer. It has long been known that firefighters have higher rates of several types of cancer than people in the general population. In a new study, researchers at the University of Ottawa examined firefighters' exposure to polycyclic aromatic hydrocarbons (PAHs) in smoke from fires. PAHs can cause genetic mutations and are known carcinogens. They are one of the hazardous substances released into the air when wood, plastics, furniture, electronics or building materials burn. The researchers collected urine samples from -- and also wiped the skin and clothing of -- more than two dozen Canadian firefighters before and after they responded to fires in 2015 and 2016. On average, the levels of PAH metabolites in urine were about three to five times higher after a fire than before a fire, the findings showed. That increase was associated with an average 4.3 times higher risk of DNA mutations. "There's a relationship between firefighters' urinary PAH metabolite levels and the levels of PAHs on their skin, which leads us to suspect that [skin] contact may be an important route of exposure," Jennifer Keir, an author on the study, said in a news release from the American Chemical Society. The researchers suggested that skin decontamination immediately after fighting a fire may help reduce exposure to these potentially cancer-causing compounds. The study was published Oct. 18 in the journal Environmental Science & Technology . SOURCE: American Chemical Society, news release, Oct. 18, 2017 HealthDay Copyright (c) 2017 HealthDay . All rights reserved. News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services. More Health News on Cancer Occupational Health Recent Health News maintaining


and feminine Firefighters Exposed to Carcinogens Through the Skin colour
license plate Skyla IUD be happy

license plate Skyla IUD be happy

try to be Skyla IUD newest
 
Photo :Skyla IUD

circle of relatives [1%:<0.1%. If perforation occurs, locate and remove Skyla. Surgery may be required. Delayed detection or removal of Skyla in case of perforation may result in migration outside the uterine cavity, adhesions, peritonitis, intestinal perforations, intestinal obstruction, abscesses and erosion of adjacent viscera. The risk of perforation may be increased if Skyla is inserted when the uterus is fixed retroverted or not completely involuted. Delay Skyla insertion a minimum of six weeks or until involution is complete following a delivery or a second trimester abortion. Clinical trials with Skyla excluded breast-feeding women. A large postmarketing safety study conducted in Europe over a 1-year observational period reported that lactation at the time of insertion of an IUD/IUS was associated with an increased risk of perforation. For users of another LNG-releasing IUS, the incidence of uterine perforation was reported as 6.3 per 1,000 insertions for lactating women, compared to 1.0 per 1,000 insertions for non-lactating women. Expulsion Partial or complete expulsion of Skyla may occur resulting in the loss of contraceptive protection. Expulsion may be associated with symptoms of bleeding or pain, or it may be asymptomatic and go unnoticed. Skyla typically decreases menstrual bleeding over time; therefore, an increase of menstrual bleeding may be indicative of an expulsion. The risk of expulsion may be increased when the uterus is not completely involuted. In clinical trials, a 3-year expulsion rate of 3.2% (54 out of 1665 subjects) was reported. Delay Skyla insertion a minimum of six weeks or until uterine involution is complete following a delivery or a second trimester abortion. Remove a partially expelled Skyla. If expulsion has occurred, Skyla may be replaced within 7 days after the onset of a menstrual period after pregnancy has been ruled out. Ovarian Cysts Because the contraceptive effect of Skyla is mainly due to its local effects within the uterus, ovulatory cycles with follicular rupture usually occur in women of fertile age using Skyla. During clinical trials, ovarian cysts (reported as adverse reactions if they were abnormal, non-functional cysts and/or had a diameter> 3 cm on ultrasound examination) were reported in 13.2% of women using Skyla. Most of these cysts are asymptomatic, although some may be accompanied by pelvic pain or dyspareunia. In most cases the ovarian cysts disappear spontaneously during two to three months observation. Evaluate persistent ovarian cysts. Surgical intervention is not usually required. Breast Cancer Women who currently have or have had breast cancer, or have a suspicion of breast cancer, should not use hormonal contraception because some breast cancers are hormone-sensitive [see Contraindications ( 4 )] . Spontaneous reports of breast cancer have been received during postmarketing experience with a LNG-releasing IUS. Observational studies of the risk of breast cancer with use of a LNG-releasing IUS do not provide conclusive evidence of increased risk. Clinical Considerations for Use and Removal Use Skyla with caution after careful assessment if any of the following conditions exist, and consider removal of the system if any of them arise during use: Coagulopathy or use of anticoagulants Migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia Exceptionally severe headache Marked increase of blood pressure Severe arterial disease such as stroke or myocardial infarction In addition, consider removing Skyla if any of the following conditions arise during use [see Contraindications ( 4 )] : Uterine or cervical malignancy Jaundice If the threads are not visible or are significantly shortened they may have broken or retracted into the cervical canal or uterus. Consider the possibility that the system may have been displaced, (for example, expelled or perforated the uterus) [see Warnings and Precautions ( 5.6 , 5.7 )]. Exclude pregnancy and verify the location of Skyla, for example, by sonography, X-ray, or by gentle exploration of the cervical canal with a suitable instrument. If Skyla is displaced, remove it. A new Skyla may be inserted at that time or during the next menses if it is certain that conception has not occurred. If Skyla is in place with no evidence of perforation, no intervention is indicated. Magnetic Resonance Imaging (MRI) Information Non-clinical testing has demonstrated that Skyla is MR Conditional. Skyla can be safely scanned only under specific conditions: Static magnetic field of 3 Tesla or less Spatial gradient field of 36,000 Gauss/cm (T/m) or less Maximum whole body averaged specific absorption rate (SAR) of 4W/kg in the First Level Controlled mode for 15 minutes of continuous scanning In non-clinical testing, the Skyla produced a temperature rise of less than 1.8 C at a maximum whole body averaged specific absorption rate (SAR) of 2.9 W/kg, for 15 minutes of MR scanning at 3T using a transit/receive body coil. MR Image quality may be compromised (that is, a small amount of artifact may occur) if the area of interest is in the exact same area or relatively close to the position of Skyla. Image artifact extended up to 5 mm from Skyla in a Gradient Echo pulse sequence. Adverse Reactions The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling: Ectopic Pregnancy [see Warnings and Precautions ( 5.1 )] Intrauterine Pregnancy [see Warnings and Precautions ( 5.2 )] Group A Streptococcal Sepsis (GAS) [see Warnings and Precautions ( 5.3 )] Pelvic Inflammatory Disease [see Warnings and Precautions ( 5.4 )] Bleeding Pattern Alterations [see Warnings and Precautions ( 5.5 )] Perforation [see Warnings and Precautions ( 5.6 )] Expulsion [see Warnings and Precautions ( 5.7 )] Ovarian Cysts [see Warnings and Precautions ( 5.8 )] Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The data described below reflect exposure to Skyla in 1,672 patients in two contraception studies, including 1,383 exposed for one year and 993 who completed the three year studies. The population was generally healthy, 18 to 40-year old females requesting contraception and predominately Caucasian (82.6%). The data cover more than 40,000 cycles of exposure. The frequencies of reported adverse drug reactions represent crude incidences. Most common adverse reactions (occurring in 5% users) were increased bleeding (7.8%), vulvovaginitis (20.2%), abdominal/pelvic pain (18.9%), acne/seborrhea (15.0%), ovarian cyst (13.2%), headache (12.4%), dysmenorrhea (8.6%), breast pain/discomfort (8.6%) and nausea (5.5%). In the contraception studies, 18% discontinued prematurely due to an adverse reaction. The most common adverse reactions leading to discontinuation (in >1% of users) were uterine bleeding complaints (4.6%), device expulsion (3.2%), acne/seborrhea (2.9%), abdominal pain (2.5%) dysmenorrhea/uterine spasms (2.0%) and pelvic pain (1.8%). Other common adverse reactions (occurring in 1% users) by System Organ Class (SOC): The frequencies of adverse reactions observed in clinical trials are summarized in Table 3 by SOC (presented as crude incidences). Table 3: Adverse reactions that occurred in at least 1% of Skyla users in clinical trials by SOC * Ovarian cysts were reported as AEs if they were abnormal, non-functional cysts and/or had a diameter >3 cm on ultrasound examination Not all bleeding alterations were captured as adverse reactions [see Warnings and Precautions (5.5)]. System Organ Class Adverse Reaction Incidence (%) (N=1,672) Reproductive System and Breast Disorders Vulvovaginitis 20.2 Ovarian cyst * 13.2 Dysmenorrhoea 8.6 Increased bleeding 7.8 Breast pain/discomfort 5.3/3.3 Genital discharge 4.2 Device expulsion (complete and partial) 3.2 Upper genital tract infection 1.4 Gastrointestinal Disorders Abdominal pain/pelvic pain 12.7/6.2 Nausea 5.5 Skin and Subcutaneous Tissue Disorders Acne/Seborrhoea 13.6/1.4 Alopecia 1.2 Nervous System Disorders Headache 12.4 Migraine 2.3 Psychiatric Disorders Depression/ Depressed mood 3.8/0.5 Postmarketing Experience The following adverse reactions have been identified during post approval use of a LNG-releasing IUS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Arterial thrombotic and venous thromboembolic events, including cases of pulmonary emboli, deep vein thrombosis and stroke Hypersensitivity including rash, urticaria, and angioedema Device breakage Drug Interactions No drug-drug interaction studies have been conducted with Skyla. Drugs or herbal products that induce enzymes, including CYP3A4, that metabolize progestins may decrease the serum concentrations of progestins. Some drugs or herbal products that may decrease the serum concentration of LNG include: Barbiturates Bosentan Carbamazepine Efavirenz Felbamate Griseofulvin Nevirapine Oxcarbazepine Phenytoin Rifabutin Rifampin St. John s wort Topiramate Significant changes (increase or decrease) in the serum concentrations of the progestin have been noted in some cases of co-administration with HIV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors. CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone levels. Consult the labeling of all concurrently used drugs to obtain further information about interactions with Skyla or the potential for enzyme alterations. USE IN SPECIFIC POPULATIONS Pregnancy The use of Skyla during an existing or suspected pregnancy is contraindicated. Many studies have found no harmful effects on fetal development associated with long-term use of contraceptive doses of oral progestins. The few studies of infant growth and development that have been conducted with progestin-only pills have not demonstrated significant adverse effects. [See Contraindications ( 4 ) and Warnings and Precautions ( 5.1 , 5.2 ).] Nursing Mothers In general, no adverse effects of progestin-only contraceptives have been found on breastfeeding performance or on the health, growth, or development of the infant. Isolated postmarketing cases of decreased milk production have been reported. Small amounts of progestins were observed to pass into the breast milk of nursing mothers who used a LNG-releasing IUS, resulting in detectable steroid levels in infant serum. [See Warnings and Precautions ( 5.6 ).] Pediatric Use Safety and efficacy of Skyla have been established in women of reproductive age. Efficacy is expected to be the same for postpubertal females under the age of 18 as for users 18 years and older. Use of this product before menarche is not indicated. Geriatric Use Skyla has not been studied in women over age 65 and is not approved for use in this population. Hepatic Impairment No studies were conducted to evaluate the effect of hepatic disease on the disposition of LNG released from Skyla [see Contraindications ( 4 )]. Renal Impairment No studies were conducted to evaluate the effect of renal disease on the disposition of LNG released from Skyla. Skyla IUD Description Skyla (levonorgestrel-releasing intrauterine system) contains 13.5 mg of LNG, a progestin, and is intended to provide an initial release rate of approximately14 mcg/day of LNG after 24 days. Levonorgestrel USP, (-)-13-Ethyl-17-hydroxy-18,19-dinor-17ฮฑ-pregn-4-en-20-yn-3-one, the active ingredient in Skyla, has a molecular weight of 312.4, a molecular formula of C 21 H 28 O 2 , and the following structural formula: Skyla Skyla consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir (hormone elastomer core) around the vertical stem. The white T-body has a loop at one end of the vertical stem and two horizontal arms at the other end. The reservoir consists of a whitish or pale yellow cylinder, made of a mixture of LNG and silicone (polydimethylsiloxane), containing a total of 13.5 mg LNG. The reservoir is covered by a semi-opaque silicone membrane, composed of polydimethylsiloxane and colloidal silica. A ring composed of 99.95% pure silver is located at the top of the vertical stem close to the horizontal arms and is visible by ultrasound. The polyethylene of the T-body is compounded with barium sulfate, which makes it radiopaque. A monofilament brown polyethylene removal thread is attached to a loop at the end of the vertical stem of the T-body. The polyethylene of the removal thread contains iron oxide as a colorant (see Figure 10). The components of Skyla, including its packaging, are not manufactured using natural rubber latex. Figure 10. Skyla Inserter Skyla is packaged sterile within an inserter. The inserter (Figure 11), which is used for insertion of Skyla into the uterine cavity, consists of a symmetric two-sided body and slider that are integrated with flange, lock, pre-bent insertion tube and plunger. The outer diameter of the insertion tube is 3.8 mm. The vertical stem of Skyla is loaded in the insertion tube at the tip of the inserter. The arms are pre-aligned in the horizontal position. The removal threads are contained within the insertion tube and handle. Once Skyla has been placed, the inserter is discarded. Figure 11: Diagram of Inserter Skyla IUD - Clinical Pharmacology Mechanism of Action The local mechanism by which continuously released LNG enhances contraceptive effectiveness of Skyla has not been conclusively demonstrated. Studies of Skyla and similar LNG IUS prototypes have suggested several mechanisms that prevent pregnancy: thickening of cervical mucus preventing passage of sperm into the uterus, inhibition of sperm capacitation or survival, and alteration of the endometrium . Pharmacodynamics Skyla has mainly local progestogenic effects in the uterine cavity. The high local levels of LNG2 lead to morphological changes including stromal pseudodecidualization, glandular atrophy, a leukocytic infiltration and a decrease in glandular and stromal mitoses. In clinical trials with Skyla, ovulation was observed in the majority of a subset of subjects studied. Evidence of ovulation was seen in 34 out of 35 women in the first year, in 26 out of 27 women in the second year, and in all 26 women in the third year . Pharmacokinetics Absorption Low doses of LNG are administered into the uterine cavity with the Skyla intrauterine delivery system. The in vivo release rate is approximately 14 mcg/day after 24 days and is reduced to approximately 10 mcg/day after 60 days and then decreases progressively to approximately 5 mcg/day after three years. The average LNG in vivo release rate is approximately 6 mcg/day over the period of three years. In a subset of 7 subjects, maximum observed serum LNG concentration was 192 105 pg/mL, reached after 2 days (median) of Skyla insertion. Thereafter, LNG serum concentration decreased after long-term use of 12, 24, and 36 months to concentrations of 77 21 pg/mL, 62 38 pg/mL, and 72 29 pg/mL, respectively. A population pharmacokinetic evaluation based on a broader data base (>1000 patients) showed similar concentration data of 168 46 pg/mL at 7 days after placement. Thereafter, LNG serum concentrations decline slowly to a value 61 19 pg/mL after 3 years. Distribution The apparent volume of distribution of LNG is reported to be approximately 1.8 L/kg. Levonorgestrel is bound non-specifically to serum albumin and specifically to sex hormone binding globulin (SHBG). Accordingly, changes in the concentration of SHBG in serum result in an increase (at higher SHBG concentration) or a decrease (at lower SHBG concentration) of the total LNG concentration in serum. In a subset of 7 subjects, the concentration of SHBG declined by a mean value of 18% within 2 weeks after insertion of Skyla and remains relatively stable over the 3 year period of use. Less than 2 % of the circulating LNG is present as free steroid. Metabolism Following absorption, LNG is conjugated at the 17ฮฒ-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in serum. Significant amounts of conjugated and unconjugated 3ฮฑ, 5ฮฒ-tetrahydrolevonorgestrel are also present in serum, along with much smaller amounts of 3ฮฑ, 5ฮฑ-tetrahydrolevonorgestrel and 16ฮฒ-hydroxylevonorgestrel. LNG and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for wide individual variations in LNG concentrations seen in individuals using LNG containing contraceptive products. In vitro studies have demonstrated that oxidative metabolism of LNG is catalyzed by CYP enzymes, especially CYP3A4. Excretion About 45% of LNG and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates. The elimination half-life of LNG after parenteral administration is approximately 20 hours. Specific Populations Pediatric: Safety and efficacy of Skyla have been established in women of reproductive age. Use of this product before menarche is not indicated . In a one-year phase 3 study in post-menarcheal female adolescents (mean age 16.2, range 12 to 18 years) using Skyla, the population pharmacokinetic analysis of 278 adolescents showed mean estimated LNG serum concentrations slightly higher (approximately 10%) in adolescents compared to prior data in adults. This correlates to the generally lower body weight in adolescents. The ranges estimated for adolescents lie within the ranges estimated for adults. Geriatric: Skyla has not been studied in women over age 65 and is not currently approved for use in this population . Race: A three-year phase 3 study in the Asian-Pacific region (93% Asian women, the majority of whom were Chinese, 7% other ethnicities) using Skyla was performed. The population pharmacokinetic analysis of the Asian (Chinese) population in this study showed that mean estimated LNG serum concentrations in Asian women were slightly higher (approximately 5 to 16% for total LNG and 4 to 12% for unbound LNG) than those in another phase 3 study which was performed in mainly Caucasian women (79.7%). This slightly higher exposure might be explained by the lower body weight of Asian women. Hepatic Impairment: No studies were conducted to evaluate the effect of hepatic disease on the disposition of Skyla . Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of Skyla. Drug-Drug Interactions No drug-drug interaction studies were conducted with Skyla [see Drug Interactions ( 7 )] . Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment of Fertility [See Warnings and Precautions ( 5.9 ).] Clinical Studies Clinical Trials on Contraception The contraceptive efficacy of Skyla was demonstrated in a clinical trial that enrolled generally healthy women aged 18 35, 1,432 of whom received Skyla. The Skyla arm included 38.8 % (556) nulliparous women. The trial was a multicenter, multi-national, randomized open label study conducted in 11 countries in Europe, Latin America, the US and Canada. Women less than six weeks postpartum, with a history of ectopic pregnancy, with clinically significant ovarian cysts or with HIV or otherwise at high risk for sexually transmitted infections were excluded. For Skyla-treated women, 540 (37.7%) were treated at US sites and 892 (62.3%) were at non-US sites. The racial demographic of enrolled women who received Skyla was: Caucasian (79.7%), Hispanic (11.5%), Black (5.2%), Asian (0.8%), and Other (2.7%). The weight range for treated women was 38 to 155 kg (mean weight: 68.7 kg) and mean BMI was 25.3 kg/m 2 (range 16 55 kg/m 2 ). Of Skyla-treated women, 21.9% discontinued the study treatment due to an adverse event, 4.4% were lost to follow up, 1.8% withdrew their consent, 13.0% discontinued due to other reason, 1.1% discontinued due to protocol deviation, and 0.6% discontinued due to pregnancy. The pregnancy rate calculated as the Pearl Index (PI) in women aged 18 35 years was the primary efficacy endpoint used to assess contraceptive reliability. The PI was calculated based on 28-day equivalent exposure cycles; evaluable cycles excluded those in which back-up contraception was used unless a pregnancy occurred in that cycle. Skyla-treated women provided 15,763 evaluable 28-day cycle equivalents in the first year and 39,368 evaluable cycles over the three year treatment period. The PI estimate for the first year of use based on the 5 pregnancies that occurred after the onset of treatment and within 7 days after Skyla removal or expulsion was 0.41 with a 95% upper confidence limit of 0.96. The cumulative 3-year pregnancy rate, based on 10 pregnancies, estimated by the Kaplan-Meier method was 0.9 per 100 women or 0.9%, with a 95% upper confidence limit of 1.7%. About 77% of women wishing to become pregnant conceived within 12 months after removal of Skyla. REFERENCES 1 Farley T M M, Rosenberg M J, Rowe P J, Chen J, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339:785-788. 2 Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of LNG in women using a LNG-releasing IUD. Clinical Endocrinol 1982; 17:529-536. How Supplied/Storage and Handling Skyla (levonorgestrel-releasing intrauterine system), containing a total of 13.5 mg LNG, is available in a carton of one sterile unit. NDC# 50419-422-01 Skyla is supplied sterile. Skyla is sterilized with ethylene oxide. Do not resterilize. For single use only. Do not use if the inner package is damaged or open. Insert before the end of the month shown on the label. Store at 25 C (77 F); with excursions permitted between 15 30 C (59 86 F) [see USP Controlled Room Temperature]. Patient Counseling Information Advise the patient to read the FDA-approved patient labeling (Patient Information) Sexually Transmitted Infections: Counsel the patient that this product does not protect against HIV infection (AIDS) and other sexually transmitted infections (STIs). Risk of Ectopic Pregnancy: Inform the patient about the risks of ectopic pregnancy, including the loss of fertility. Teach her to recognize and report to her healthcare provider promptly any symptoms of ectopic pregnancy. [See Warnings and Precautions (5.1).] Pregnancy or Suspected Pregnancy: Counsel the patient to inform her healthcare provider if she determines or suspects she is pregnant with Skyla in place. Pelvic Infection: Inform the patient about the possibility of pelvic inflammatory disease (PID) and that PID can cause tubal damage leading to ectopic pregnancy or infertility, or infrequently can necessitate hysterectomy, or cause death. Teach the patient to recognize and report to her healthcare provider promptly any symptoms of PID. These symptoms include development of menstrual disorders (prolonged or heavy bleeding), unusual vaginal discharge, abdominal or pelvic pain or tenderness, dyspareunia, chills, and fever. [See Warnings and Precautions ( 5.4 ).] Bleeding Pattern Alterations: Counsel the patient that irregular or prolonged bleeding and spotting, and/or cramps may occur during the first few weeks after insertion. If her symptoms continue or are severe she should report them to her healthcare provider. [See Warnings and Precautions (5.5).] Perforation and Expulsion: Counsel the patient that the IUS may be expelled from or perforate the uterus and instruct her on how she can check that the threads still protrude from the cervix. Caution her not to pull on the threads and displace Skyla. Inform her that there is no contraceptive protection if Skyla is displaced or expelled. [See Warnings and Precautions (5.6, 5.7).] Clinical Considerations for Use and Removal: Instruct the patient to contact her healthcare provider if she experiences any of the following: A stroke or heart attack Very severe or migraine headaches Unexplained fever Yellowing of the skin or whites of the eyes, as these may be signs of serious liver problems Pregnancy or suspected pregnancy Pelvic pain or pain during sex HIV positive seroconversion in herself or her partner Possible exposure to sexually transmitted infections (STIs) Unusual vaginal discharge or genital sores Severe vaginal bleeding or bleeding that lasts a long time, or if she misses a menstrual period Inability to feel Skyla's threads Magnetic Resonance Imaging (MRI) Information: Inform the patient that Skyla can be safely scanned with MRI only under specific conditions [see Warnings and Precautions (5.11)] . Instruct patients who will have an MRI to tell their doctor that they have Skyla. This information is included on the Follow-Up Reminder Card. Complete the Follow-up Reminder Card and give to the patient. FDA-Approved Patient Labeling Patient Information Skyla (sky-lah) (levonorgestrel-releasing intrauterine system) Skyla does not protect against HIV infection (AIDS) and other sexually transmitted infections (STIs). Read this Patient Information carefully before you decide if Skyla is right for you. This information does not take the place of talking with your gynecologist or other healthcare provider who specializes in women s health. If you have any questions about Skyla, ask your healthcare provider. You should also learn about other birth control methods to choose the one that is best for you. What is Skyla? Skyla is a hormone-releasing system placed in your uterus by your healthcare provider to prevent pregnancy for up to 3 years. Skyla can be removed by your healthcare provider at any time. Skyla can be used whether or not you have had a child. Skyla is a small, flexible plastic T-shaped system that slowly releases a progestin hormone called levonorgestrel that is often used in birth control pills. Because Skyla releases levonorgestrel into your uterus, only small amounts of the hormone enter your blood. Skyla does not contain estrogen. Two thin threads are attached to the stem of Skyla. The threads are the only part of Skyla you can feel when Skyla is in your uterus; however, unlike a tampon string, the threads do not extend outside your body. Skyla is small and flexible What if I need birth control for more than 3 years? Skyla must be removed after 3 years. Your healthcare provider can place a new Skyla during the same office visit if you choose to continue using Skyla. What if I want to stop using Skyla? Skyla is intended for long-term use but you can stop using Skyla at any time by asking your healthcare provider to remove it. You could become pregnant as soon as Skyla is removed, so you should use another method of birth control if you do not want to become pregnant. What if I change my mind about birth control and want to become pregnant in less than 3 years? Your healthcare provider can remove Skyla at any time. You may become pregnant as soon as Skyla is removed. About 3 out of 4 women who want to become pregnant will become pregnant sometime in the first year after Skyla is removed. How does Skyla work? Skyla may work in several ways including thickening cervical mucus, inhibiting sperm movement, reducing sperm survival, and thinning the lining of your uterus. It is not known exactly how these actions work together to prevent pregnancy. How well does Skyla work for contraception? The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant. Skyla, an intrauterine device (IUD), is in the box at the top of the chart. Who might use Skyla? You might choose Skyla if you: Want long-term birth control that provides a low chance of getting pregnant (less than 1 in 100) Want birth control that works continuously for up to 3 years Want birth control that is reversible Want a birth control method that you do not need to take daily Are willing to use a birth control method that is placed in the uterus Want birth control that does not contain estrogen Who should not use Skyla? Do not use Skyla if you: Are or might be pregnant; Skyla cannot be used as an emergency contraceptive Have had a serious pelvic infection called pelvic inflammatory disease (PID) unless you have had a normal pregnancy after the infection went away Have an untreated pelvic infection now Have had a serious pelvic infection in the past 3 months after a pregnancy Can get infections easily. For example, if you have: o Multiple sexual partners or your partner has multiple sexual partners Problems with your immune system Intravenous drug abuse Have or suspect you might have cancer of the uterus or cervix Have bleeding from the vagina that has not been explained Have liver disease or liver tumor Have breast cancer or any other cancer that is sensitive to progestin (a female hormone), now or in the past Have an intrauterine device in your uterus already Have a condition of the uterus that changes the shape of the uterine cavity, such as large fibroid tumors Are allergic to levonorgestrel, silicone, polyethylene, silver, silica, barium sulfate or iron oxide Before having Skyla placed, tell your healthcare provider if you: Have had a heart attack Have had a stroke Were born with heart disease or have problems with your heart valves Have problems with blood clotting or take medicine to reduce clotting Have high blood pressure Recently had a baby or if you are breastfeeding Have severe migraine headaches How is Skyla placed? Skyla is placed by your healthcare provider during an in-office visit. First, your healthcare provider will examine your pelvis to find the exact position of your uterus. Your healthcare provider will then clean your vagina and cervix with an antiseptic solution and slide a slim plastic tube containing Skyla into your uterus. Your healthcare provider will then remove the plastic tube, and leave Skyla in your uterus. Your healthcare provider will cut the threads to the right length. Placement takes only a few minutes. You may experience pain, bleeding or dizziness during and after placement. If your symptoms do not pass within 30 minutes after placement, Skyla may not have been placed correctly. Your healthcare provider will examine you to see if Skyla needs to be removed or replaced. Should I check that Skyla is in place? Yes, you should check that Skyla is in proper position by feeling the removal threads. It is a good habit to do this once a month. Your healthcare provider should tell you how to check that Skyla is in place. First, wash your hands with soap and water. You can check by reaching up to the top of your vagina with clean fingers to feel the removal threads. Do not pull on the threads. If you feel more than just the threads or if you cannot feel the threads, Skyla may not be in the right position and may not prevent pregnancy. Use non-hormonal back-up birth control (such as condoms and spermicide) and ask your healthcare provider to check that Skyla is still in the right place. How soon after placement of Skyla should I return to my healthcare provider? Call your healthcare provider if you have any questions or concerns (see When should I call my healthcare provider ). Otherwise, you should return to your healthcare provider for a follow-up visit 4 to 6 weeks after Skyla is placed to make sure that Skyla is in the right position. Can I use tampons with Skyla? Tampons may be used with Skyla. What if I become pregnant while using Skyla? Call your healthcare provider right away if you think you are pregnant. If you get pregnant while using Skyla, you may have an ectopic pregnancy. This means that the pregnancy is not in the uterus. Unusual vaginal bleeding or abdominal pain may be a sign of ectopic pregnancy. Ectopic pregnancy is a medical emergency that often requires surgery. Ectopic pregnancy can cause internal bleeding, infertility, and even death. There are also risks if you get pregnant while using Skyla and the pregnancy is in the uterus. Severe infecti moms and dads


the workers Skyla IUD in good shape
fee Arthritis Can Strike Children of goods

fee Arthritis Can Strike Children of goods

eliminate Arthritis Can Strike Children conflict
 
Photo :Arthritis Can Strike Children

profiting from (*this news item will not be available after 01/16/2018) By Robert Preidt Wednesday, October 18, 2017 TUESDAY, Oct. 17, 2017 (HealthDay News) -- While arthritis is typically thought of as an older person's disease, more than 300,000 American children have chronic juvenile idiopathic arthritis (JIA), an expert says. Unlike age-related arthritis caused by cartilage and bone wear and tear, JIA has more to do with joint inflammation, but it's not clear what triggers this inflammation, said Dr. Barbara Ostrov, a pediatric and adult rheumatologist at Penn State Health in Hershey, Pa. Symptoms of JIA include joints that are consistently swollen, stiff or inflamed. In some cases, the disease also affects the eyes and can threaten vision if not diagnosed and treated promptly. All children with JIA should be monitored by an ophthalmologist. The youngest children with JIA often don't complain about their pain. Signs that they may have JIA include wanting to be carried for the first couple of hours a day due to morning stiffness, or a persistently swollen knee or limp. "In many cases, children just work around the problem and do function with minor adjustments in how they use the affected joints. But the older kids tend to perceive their arthritis differently and may have more discomfort," Ostrov said in a university news release. For children with JIA who have inflammation in one or two joints, cortisone shots may offer relief for up to two years. Also, low doses of the medication methotrexate can help ease symptoms and inflammation in many patients. If inflammation persists, doctors may prescribe biologic drugs to dampen an overactive immune response. "We are fortunate to have medications to control this inflammation. Children tend to do well on them, with fewer side effects than adults," Ostrov said. The outlook for children with JIA is much better now than it was decades ago, she added. "In the 1980s and 90s we had kids who needed hips, knees and other joints replaced with new joints. But now, having JIA is more about taking medication safely, monitoring symptoms and living well with arthritis," Ostrov said. SOURCE: Penn State Health Milton S. Hershey Medical Center, news release, Oct. 11, 2017 HealthDay Copyright (c) 2017 HealthDay . All rights reserved. News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services. More Health News on Children's Health Recent Health News normal


and so forth Arthritis Can Strike Children studying
weighing machine People Deemed Better Looking, Better Off After a Nose Job immediately

weighing machine People Deemed Better Looking, Better Off After a Nose Job immediately

your business People Deemed Better Looking, Better Off After a Nose Job package
 
Photo :People Deemed Better Looking, Better Off After a Nose Job

the complete opposite (*this news item will not be available after 01/17/2018) Thursday, October 19, 2017 THURSDAY, Oct. 19, 2017 (HealthDay News) -- Is a "nose job" worth it? And if so, how much? A new study suggests that casual observers may think patients who undergo such procedures are more attractive, more successful and healthier. "While we are not suggesting that [a nose job] is the only way to improve one's appearance, improving our attractiveness and health as compared to others conveys a competitive advantage," said study co-author and plastic surgeon Dr. Lisa Ishii. More than 220,000 "nose reshaping" procedures -- known as rhinoplasty -- were performed in the United States in 2016, up 2 percent from the previous year, according to the American Society of Plastic Surgeons. The procedures are nearly as common as liposuction. The new study examines how "casual observers" perceive people after they've had a nose job, said Ishii, a plastic surgeon and associate professor at Johns Hopkins School of Medicine in Baltimore. "Patients seeking rhinoplasty do so for two main reasons: to improve their self-perception and to improve how others perceive them," she said. "We wanted to measure the second one." The researchers recruited 473 people online to evaluate the appearance of 13 rhinoplasty patients. Observers ranged in age from 18 to 73. Most were female and white, and highly educated. The researchers deemed the patients' post-op results "optimal." They showed the observers photos taken before the nose reshaping and at least 6 months after. But they didn't reveal whether they were "before" or "after" images, and the observers never saw more than one picture of the same patient. The patients were mostly female, with an average age of 34. Most "had nose problems that were visible to the casual observer and they wanted to look better," Ishii said. She added that a prior study showed that the casual observer "actually picks up on even subtle nasal deformities." Her team asked the observers to rate patients in terms of attractiveness, success level and overall health based on their photos. On a scale of 1 to 100, the average patient's attractiveness rating improved by 14 points after remodeling, the researchers found. Ratings of success and health rose 9 and 10 points, respectively, after surgery. Ishii called the degree of improvement significant, and said this gives patients information about how nose jobs may affect them. "More attractive people are more successful," she said. "It's up to patients to decide whether that's worth it to them." Insurers don't usually cover nose jobs, however. The cost can range from $6,000 to $25,000 "depending on the complexity of the procedure and the reputation of the surgeon," said plastic surgeon Dr. Clinton Humphrey. He's an associate professor with the University of Kansas Health System. "It is important not to misinterpret these study results," cautioned Humphrey, co-author of a commentary accompanying the new research. "This study included only patients with what were judged by surgeons to be 'ideal' results. Rhinoplasty continues to be one of the most challenging cosmetic surgical procedures," he said. "While I always strive to achieve the best possible outcome in every one of my rhinoplasty patients, I do not achieve an 'ideal' result every time," Humphrey said. "It would be a mistake to read this study and conclude that every patient who undergoes rhinoplasty can expect to be perceived as more successful, healthier, and more attractive," he added. Still, he said, "patients should feel reassured that what we as rhinoplasty surgeons consider to be 'ideal' results are also viewed very favorably by the average person," Humphrey said. "As a surgeon, this study tells me that when I execute a successful rhinoplasty, I have an opportunity to positively impact my patient in a really significant way." The study appears Oct. 19 in the journal JAMA Facial Plastic Surgery . SOURCE: Lisa Ishii, M.D., plastic surgeon and associate professor, Johns Hopkins School of Medicine, Baltimore; Clinton Humphrey, M.D., associate professor, University of Kansas Health System; Oct. 19, 2017, JAMA Facial Plastic Surgery HealthDay Copyright (c) 2017 HealthDay . All rights reserved. News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services. More Health News on Plastic and Cosmetic Surgery Recent Health News pictures


to 15 People Deemed Better Looking, Better Off After a Nose Job delivery
fabulous Self-Harm on the Rise Among Teen Girls surgery

fabulous Self-Harm on the Rise Among Teen Girls surgery

trouble Self-Harm on the Rise Among Teen Girls smart decision
 
Photo :Self-Harm on the Rise Among Teen Girls

is not sensible (*this news item will not be available after 01/17/2018) By Robert Preidt Thursday, October 19, 2017 THURSDAY, Oct. 19, 2017 (HealthDay News) -- Teen girls are much more likely to self-harm than boys, and the dangerous practice is on the rise. That's the conclusion of a new British study that also found a strong link between self-harm -- practices such as cutting or burning oneself -- and a higher risk of suicide. Researchers reviewed information from nearly 650 general practices in the United Kingdom. The records had data on almost 9,000 patients aged 10 to 19 who self-harmed between 2001 and 2014. The investigators compared those children to more than 170,000 kids who didn't self-harm, matched for age and gender. The rate of self-harm was about three times higher among girls than boys. The rate rose 68 percent among girls ages 13 to 16 from 2011 to 2014. Referrals to mental health services within 12 months of self-harming were 23 percent less likely for children in the poorest areas, even though the rates of self-harm were higher in these areas. The researchers also found that children and teens who self-harmed had a nine times increased risk of death from non-natural causes. The risk from suicide and alcohol/drug poisoning was especially pronounced. The high self-harm rate among teen girls may be due to common mental health problems in females at this age. Biological factors such as puberty and onset of sexual activity may also play a role in self-harm, according to lead researcher Cathy Morgan, from the University of Manchester, and colleagues. The researchers said there is some evidence that common mental health disorders are on the rise among teens. This may be because they "are living in more stressful times," Morgan's team said. The study findings "emphasize the urgent need for integrated care involving families, schools and health care provision to enhance safety among these distressed young people in the short term, and to help secure their future mental health and well-being," the study authors concluded. The study was published Oct. 18 in BMJ . SOURCE: BMJ , news release, Oct. 18, 2017 HealthDay Copyright (c) 2017 HealthDay . All rights reserved. News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services. More Health News on Health Disparities Self-harm Teen Mental Health Recent Health News preferable


is famous Self-Harm on the Rise Among Teen Girls the child